Recent developments in CCR5 regulation for HIV cure.

Area of Science:

• Immunology
• Virology
• Gene Therapy

Background:

• Acquired immunodeficiency syndrome (AIDS), caused by human immunodeficiency virus (HIV), remains a global health challenge despite available treatments.
• HIV primarily infects CD4+ T cells, utilizing CD4 as a receptor and often requiring the CCR5 co-receptor for cell entry.
• Current HIV treatments improve life expectancy but do not offer a cure.

Purpose of the Study:

• To review strategies for CCR5-gene disruption in CD4+ T cells and hematopoietic stem cells (HSCs).
• To explore the potential of generating an HIV-resistant immune system through CCR5-targeted gene therapy.
• To discuss the implications of CCR5 gene modification for new clinical approaches in HIV treatment.

Main Methods:

• Review of current gene disruption strategies targeting the CCR5 co-receptor.
• Analysis of methods for modifying CD4+ T cells and HSCs to confer HIV resistance.
• Examination of the role of CCR5 in HIV entry and the impact of its genetic disruption.

Main Results:

• CCR5-gene disruption presents a promising avenue for developing HIV resistance.
• Targeting CCR5 in T cells and HSCs can potentially create a more robust immune defense against HIV.
• The review highlights the feasibility of generating HIV-resistant cells through gene-editing techniques.

Conclusions:

• CCR5-gene disruption strategies offer novel approaches for HIV treatment and clinical trials.
• While promising, these gene therapy techniques have limitations and require combination with other strategies for a complete HIV remedy.
• Further research is needed to address potential HIV re-emergence and optimize CCR5-targeted therapies for long-term HIV management.